↓ Skip to main content

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Overview of attention for article published in Frontiers in Pharmacology, April 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
Published in
Frontiers in Pharmacology, April 2022
DOI 10.3389/fphar.2022.871259
Pubmed ID
Authors

Meng Wu, Jingyi Cui, Huimin Hou, Ying Li, Shengjie Liu, Li Wan, Lili Zhang, Wei Huang, Gaoyuan Sun, Jingchao Liu, Pengfei Jin, Shunmin He, Ming Liu

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 25%
Student > Bachelor 1 13%
Other 1 13%
Student > Doctoral Student 1 13%
Unknown 3 38%
Readers by discipline Count As %
Unspecified 2 25%
Agricultural and Biological Sciences 1 13%
Medicine and Dentistry 1 13%
Unknown 4 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2022.
All research outputs
#15,687,628
of 23,312,088 outputs
Outputs from Frontiers in Pharmacology
#6,727
of 16,764 outputs
Outputs of similar age
#250,643
of 442,849 outputs
Outputs of similar age from Frontiers in Pharmacology
#447
of 1,221 outputs
Altmetric has tracked 23,312,088 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,764 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,849 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,221 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.